1. In Vivo
  2. >>Innovation

Alchemab Is Bringing A New Meaning To Patient-Centered Care

British-Bostonian Biotech Is Working Backwards To Explain Disease Resilience

 
• By Chloe Kent

Alchemab Therapeutics sequences the antibodies of patients who prove especially resilient to hard-to-treat diseases to try and find therapeutic targets.

Depiction of an antibody
Alchemab is sequencing patients' B-cells in the hope of finding treatments for serious illnesses • Source: Shutterstock

At Alchemab Therapeutics the first step in the drug discovery journey starts not in a laboratory but with an individual person – not a scientist or researcher, but a patient. The biotech aims to target diseases across neurology and oncology through naturally occurring protective antibodies, mining the antibody receptors of individuals who are especially resistant to or have even recovered from serious illness to develop therapeutic products.

“Alchemab was founded on the idea that there are people who are resilient to disease, or perhaps just unusually well,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Akelos’ Peripheral HCN1 Blocker Looks To End Opioid Dependence In Neuropathic Pain

 
• By Jo Shorthouse

Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.